1. Home
  2. MDWD vs UAMY Comparison

MDWD vs UAMY Comparison

Compare MDWD & UAMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • UAMY
  • Stock Information
  • Founded
  • MDWD 2000
  • UAMY 1968
  • Country
  • MDWD Israel
  • UAMY United States
  • Employees
  • MDWD N/A
  • UAMY N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • UAMY Metal Fabrications
  • Sector
  • MDWD Health Care
  • UAMY Industrials
  • Exchange
  • MDWD Nasdaq
  • UAMY Nasdaq
  • Market Cap
  • MDWD 230.6M
  • UAMY 251.9M
  • IPO Year
  • MDWD 2014
  • UAMY N/A
  • Fundamental
  • Price
  • MDWD $19.09
  • UAMY $2.74
  • Analyst Decision
  • MDWD Strong Buy
  • UAMY Strong Buy
  • Analyst Count
  • MDWD 2
  • UAMY 4
  • Target Price
  • MDWD $35.00
  • UAMY $3.38
  • AVG Volume (30 Days)
  • MDWD 59.0K
  • UAMY 3.6M
  • Earning Date
  • MDWD 08-13-2025
  • UAMY 08-08-2025
  • Dividend Yield
  • MDWD N/A
  • UAMY N/A
  • EPS Growth
  • MDWD N/A
  • UAMY N/A
  • EPS
  • MDWD N/A
  • UAMY N/A
  • Revenue
  • MDWD $19,213,000.00
  • UAMY $18,865,900.00
  • Revenue This Year
  • MDWD $20.80
  • UAMY $270.45
  • Revenue Next Year
  • MDWD $26.92
  • UAMY $104.06
  • P/E Ratio
  • MDWD N/A
  • UAMY N/A
  • Revenue Growth
  • MDWD N/A
  • UAMY 97.46
  • 52 Week Low
  • MDWD $12.78
  • UAMY $0.27
  • 52 Week High
  • MDWD $24.00
  • UAMY $3.86
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 37.96
  • UAMY 47.10
  • Support Level
  • MDWD $19.98
  • UAMY $2.71
  • Resistance Level
  • MDWD $20.95
  • UAMY $3.10
  • Average True Range (ATR)
  • MDWD 0.64
  • UAMY 0.30
  • MACD
  • MDWD -0.38
  • UAMY -0.00
  • Stochastic Oscillator
  • MDWD 0.29
  • UAMY 27.43

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

Share on Social Networks: